Key Takeaways
- BIIB surged to a 52-week peak of $225.88, gaining 61.6% year-over-year
- Nykredit A/S initiated an $8.02 million position in Biogen during the second quarter
- Second quarter earnings per share of $3.60 surpassed analyst expectations of $2.94; revenue reached $2.74B, exceeding projections
- Wall Street consensus stands at “Moderate Buy” with a mean price target of $230.14
- Wolfe Research elevated BIIB to “Outperform” status with a $300 target in August
Biogen stock recorded a fresh 52-week peak of $225.88 this Monday, extending an impressive rally that has propelled shares up 61.6% over the trailing twelve months.
Shares began Tuesday’s session at $219.07, advancing approximately 1.7% during trading hours. The stock’s 50-day moving average currently rests at $211.20, while the 200-day moving average stands at $198.54.
The biotech giant’s shares touched a 1-year low of $135.39, representing a remarkable turnaround from levels witnessed just twelve months prior.
The company’s market capitalization hovers between approximately $32.37 billion and $33.26 billion across recent sessions, with its price-to-earnings ratio ranging from 38.77 to 39.41.
Quarterly Performance Drives Stock Rally
Biogen’s upward trajectory has been supported by impressive financial performance. The company delivered quarterly earnings per share of $3.60, exceeding Wall Street’s consensus forecast of $2.94 by a substantial $0.66 margin.
Quarterly revenue reached $2.74 billion, surpassing the $2.46 billion analyst projection while registering 3.4% growth compared to the prior-year period.
Looking ahead to fiscal 2026, Biogen has issued earnings per share guidance ranging from $12.00 to $13.00. The Street currently models $12.41 in EPS for the full fiscal year.
Institutional capital continues flowing into the stock. Nykredit A/S established a fresh position of 37,134 BIIB shares during Q2, representing approximately $8.02 million in value.
Additional institutional players expanded their existing stakes. Wedbush Securities increased its position by 5.1% in the second quarter. Rothschild Investment, Meeder Advisory, Kera Capital, and Parallel Advisors each augmented their holdings during earlier quarters this year.
Institutional ownership of Biogen now accounts for 87.93% of total shares outstanding.
Wall Street Upgrades and Price Target Increases
Sell-side analysts have grown increasingly bullish on the biotechnology stock. Wolfe Research elevated BIIB from “Peer Perform” to “Outperform” this August, establishing a $300 price objective.
Oppenheimer maintained its “Outperform” stance while reaffirming a $300 target. Canaccord Genuity lifted its price objective from $245 to $248 while keeping a Buy recommendation.
RBC Capital increased its target to $260 from a prior $240, highlighting the lupus therapy litifilimab as a significant upcoming catalyst. H.C. Wainwright similarly adjusted its target upward to $251 from $237, citing the same therapeutic development.
Piper Sandler boosted its price objective to $245 from $225, referencing improved forecast models for key drugs including Vumerity and Syfovre. Stifel maintains a Buy rating with a $242 target.
Across 33 covering analysts, the prevailing consensus stands at “Moderate Buy,” with a mean price target of $230.14.
According to InvestingPro’s Fair Value analysis, the shares may remain undervalued at present trading levels.
The company recently announced plans to implement Veeva Systems’ Vault CRM across its global operations, a strategic initiative Raymond James analysts highlighted as part of an emerging pharmaceutical industry pattern.
Phase 3 clinical trial data for litifilimab in lupus treatment is anticipated later this year, with Stifel among the firms expressing optimism regarding the potential outcomes.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
